Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study

Narod, 1995, An evaluation of genetic heterogeneity in 145 breast-ovarian cancer families, Am J Hum Genet, 56, 254

Ford, 1998, Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families, Am J Hum Genet, 62, 676, 10.1086/301749

Struewing, 1997, The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews, N Engl J Med, 336, 1401, 10.1056/NEJM199705153362001

Thorlacius, 1998, Population-based study of risk of breast cancer in carriers of BRCA2 mutation, Lancet, 352, 1337, 10.1016/S0140-6736(98)03300-5

Verhoog, 1998, Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1, Lancet, 251, 316, 10.1016/S0140-6736(97)07065-7

Robson, 1998, BRCA-associated breast cancer in young women, J Clin Oncol, 16, 1642, 10.1200/JCO.1998.16.5.1642

Hartmann, 1998, Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer, N Engl J Med, 340, 77, 10.1056/NEJM199901143400201

Burke, 1997, Recommendations for follow-up care of individuals with an inherited predisposition to cancer: BRCA1 and BRCA2, JAMA, 277, 997, 10.1001/jama.1997.03540360065034

Fisher, 1998, Tamoxifen for prevention of breast cancer; report of the National Surgical Adjuvant Breast and Bowel Project PI study, J Natl Cancer Inst, 90, 1371, 10.1093/jnci/90.18.1371

1998, Tamoxifen for early breast cancer: an overview of the randomised trials, Lancet, 351, 1451, 10.1016/S0140-6736(97)11423-4

Hogervorst, 1995, Rapid detection of BRCA1 mutations by the protein truncation test, Nat Genet, 10, 208, 10.1038/ng0695-208

Tonin, 1996, Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families, Nat Med, 11, 1179, 10.1038/nm1196-1179

Tonin, 1998, Founder BRCA1 and BRCA2 mutations in French-Canadian breast and ovarian cancer families, Am J Hum Genet, 63, 1341, 10.1086/302099

Karp, 1997, Influence of BRCA1 mutations on nuclear grade and estrogen receptor status in breast cancers in Ashkenazi Jewish women, Cancer, 80, 435, 10.1002/(SICI)1097-0142(19970801)80:3<435::AID-CNCR11>3.0.CO;2-Y

Johannsson, 1997, Tumour biological features of BRCA1-induced breast and ovarian cancer, Eur J Cancer, 33, 362, 10.1016/S0959-8049(97)89007-7

Loman, 1998, Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes, Cancer, 83, 310, 10.1002/(SICI)1097-0142(19980715)83:2<310::AID-CNCR15>3.0.CO;2-W

Eisenger, 1999, Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes, Cancer, 85, 2291, 10.1002/(SICI)1097-0142(19990515)85:10<2291::AID-CNCR26>3.0.CO;2-9

Narod, 1995, Risk modifiers in carriers of BRCA1 mutations, Int J Cancer, 64, 394, 10.1002/ijc.2910640608

Easton, 1995, Breast and ovarian cancer incidence in BRCA1 mutation carriers, Am J Hum Genet, 56, 265

Rebbeck, 1999, Reduction in breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers, J Natl Cancer Inst, 91, 1475, 10.1093/jnci/91.17.1475

Jernström, 1999, Pregnancy and risk of early onset breast cancer in carriers of BRCA1 and BRCA2, Lancet, 354, 1846, 10.1016/S0140-6736(99)04336-6

Brunet, 1998, The effect of smoking on breast cancer incidence in BRCA1 and BRCA2 carriers, J Natl Cancer Inst, 90, 761, 10.1093/jnci/90.10.761

Fan, 1999, BRCA1 inhibition of estrogen receptor signalling in transfected cells, Science, 284, 1354, 10.1126/science.284.5418.1354

Veronesi, 1998, Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomized trial among hysterectomised women, Lancet, 352, 93, 10.1016/S0140-6736(98)85011-3

Powles, 1998, Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial, Lancet, 352, 98, 10.1016/S0140-6736(98)05071-5

Ford, 1994, Risks of cancer in BRCA1-mutation carriers, Lancet, 343, 692, 10.1016/S0140-6736(94)91578-4

1999, Cancer risks in BRCA2 carriers, J Natl Cancer Inst, 91, 1310, 10.1093/jnci/91.15.1310

Moslehi, 2000, BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer, Am J Hum Genet, 66, 1259, 10.1086/302853

Cummings, 1999, The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial, JAMA, 281, 2189, 10.1001/jama.281.23.2189

Chen, 1999, Epidemiology of contralateral breast cancer, Cancer Epidemiol Biomarkers Prev, 8, 855

1997, Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases, Lancet, 349, 1505, 10.1016/S0140-6736(96)10109-4

Crook, 1997, p53 mutations in BRCA1-associated familial breast cancer, Lancet, 350, 638, 10.1016/S0140-6736(05)63327-2

Meakin, 1996, Ovarian irradiation and prednisone following surgery and radiotherapy for carcinoma of the breast, Breast Cancer Res Treat, 37, 11, 10.1007/BF01806627

O'Reagan, 1999, Tamoxifen and contralateral breast cancer, J Am Coll Surg, 188, 678, 10.1016/S1072-7515(99)00057-5